EpiCast Report: Chronic Lymphocytic Leukemia – Epidemiology Forecast to 2025

Chronic lymphocytic leukemia (CLL), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection. CLL is closely related to small lymphocytic lymphoma (SLL), a type of non-Hodgkin's lymphoma that presents primarily in the lymph nodes

GlobalData epidemiologists utilized national databases and robust peer-reviewed journal articles to build the CLL diagnosed incident and five-year diagnosed prevalent cases forecast in the 7MM. The disease definition for CLL was consistent with the ICD-10 code C91.1. Whenever available, country-specific sources were utilized and in case of data scarcity, appropriate proxies were used to fill the data gaps.

In the 7MM, GlobalData epidemiologists forecast an increase in the diagnosed incident cases of CLL from 40,631 diagnosed incident cases in 2015 to 49,643 diagnosed incident cases in 2025, with an annual growth rate (AGR) of 2.22% during the forecast period. The US will have the highest number of diagnosed incident cases of CLL among the 7MM throughout the forecast period, while Spain will have the lowest.

Scope

The Chronic lymphocytic leukemia (CLL) EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of CLLin the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CLL and five-year diagnosed prevalent cases of CLL. Incident cases are segmented by age, sex, Rai and Binet stage at diagnosis, symptom status (symptomatic vs. asymptomatic), and immunoglobulin heavy chain variable (IGHV) region gene mutation status (mutated vs. unmutated) for the 7MM. The diagnosed incident cases of CLL with the mutations 17p deletion, 11q deletion, and TP53 are also provided in the report.

The CLL epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The CLL EpiCast series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global CLL market.

Quantify patient populations in the global CLL market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CLL therapeutics in each of the markets covered.

Understand magnitude of CLL population by two staging systems.

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.4.3 Diagnosed Incident Cases

3.4.4 Diagnosed Incident Cases by Stage at Diagnosis (Rai Staging)

3.4.5 Diagnosed Incident Cases by Stage at Diagnosis (Binet Staging)

3.4.6 Diagnosed Incident Cases by Disease Symptom Status

3.4.7 Mutations (17p deletion, 11q Deletion, and TP53) Among the Diagnosed Incident Cases of CLL

3.4.8 IGHV Mutation Among Diagnosed Incident Cases of CLL

3.4.9 Five-Year Diagnosed Prevalent Cases of CLL

3.5 Epidemiological Forecast for CLL (2015–2025)

3.5.1 Diagnosed Incident Cases of CLL

3.5.2 Age-Specific Diagnosed Incident Cases of CLL

3.5.3 Sex-Specific Diagnosed Incident Cases of CLL

3.5.4 Diagnosed Incident Cases of CLL by Stage at Diagnosis (Rai Staging)

3.5.5 Diagnosed Incident Cases of CLL by Stage at Diagnosis (Binet Staging)

3.5.6 Diagnosed Incident Cases of CLL by Disease Symptom Status

3.5.7 Diagnosed Incident Cases of CLL with 17p Deletion

3.5.8 Diagnosed Incident Cases of CLL with 11q Deletion

3.5.9 Diagnosed Incident Cases of CLL with TP53 Mutation

3.5.10 Diagnosed Incident Cases of CLL by IGHV Mutation Status

3.5.11 Five-Year Diagnosed Prevalent Cases of CLL

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 Limitations of Analysis

3.6.3 Strengths of Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

List of Tables

Table 1: CLL Clinical Stages

Table 2: Risk Factors and Comorbidities for CLL

Table 3: 7MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥18 Years, Selected Years 2015–2025.

Table 4: 7MM, Five-Year Diagnosed Prevalent Cases of CLL, Both Sexes, Ages ≥18 Years, Selected Years 2015–2025

List of Figures

Figure 1: 7MM, Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥18 Years, 2015 and 2025

Figure 2: 7MM, Five-Year Diagnosed Prevalent Cases of CLL, Both Sexes, Ages ≥18 Years , 2015 and 2025

Figure 3: 7MM, CLL Age-Standardized Diagnosed Incidence (Cases per 100,000 Population), Men, Ages ≥18 Years, 2005 to 2025

Figure 4: 7MM, CLL Age-Standardized Diagnosed Incidence (Cases per 100,000 Population), Women, Ages ≥18 Years, 2005 to 2025

Figure 5: 7MM, Sources Used, Diagnosed Incident Cases of CLL

Figure 6: 7MM, Sources Used, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Rai Staging)

Figure 7: 7MM, Sources Used, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Binet Staging)

Figure 8: 7MM, Sources Used, 17p Deletion Among the Diagnosed Incident Cases of CLL

Figure 9: 7MM, Sources Used, 11q Deletion Among the Diagnosed Incident Cases of CLL

Figure 10: 7MM, Sources Used, TP53 Mutation Among the Diagnosed Incident Cases of CLL

Figure 11: 7MM, Sources Used, Diagnosed Incident Cases of CLL by IGHV Mutation Status

Figure 12: 7MM, Sources Used and Not Used, Five-Year Diagnosed Prevalent Cases of CLL

Figure 13: 7MM, Age-Specific Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥18 Years, 2015

Figure 14: 7MM, Sex-Specific Diagnosed Incident Cases of CLL, Both Sexes, Ages ≥18 Years, 2015

Figure 15: 7MM, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Rai Staging), Both Sexes, Ages ≥18 Years, 2015

Figure 16: 7MM, Diagnosed Incident Cases of CLL by Stage at Diagnosis (Binet Staging), Both Sexes, Ages ≥18 Years, 2015

Figure 17: 7MM, Diagnosed Incident Cases of CLL by Disease Symptom Status, Both Sexes, Ages ≥18 Years, 2015

Figure 18: 7MM, Diagnosed Incident Cases of CLL with 17p Deletion, Both Sexes, Ages ≥18 Years, 2015

Figure 19: 7MM, Diagnosed Incident Cases of CLL with 11q Deletion, Both Sexes, Ages ≥18 Years, 2015

Figure 20: 7MM, Diagnosed Incident Cases of CLL with TP53 Mutation, Both Sexes, Ages ≥18 Years, 2015

Figure 21: 7MM, Diagnosed Incident Cases of CLL by IGHV Mutational Status, Both Sexes, Ages ≥18 Years, 2015

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports